Editorial
doi: 10.1097/IAE.0b013e3181cde727.
More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial
- PMID: 20061905
- PMCID: PMC3893927
- DOI: 10.1097/IAE.0b013e3181cde727
Item in Clipboard
Editorial
More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial
Retina.
2010 Jan.
No abstract available
Similar articles
-
Adverse events after intravitreal infliximab (Remicade).Retina. 2010 Jan;30(1):71-80. doi: 10.1097/IAE.0b013e3181bcef3b. Retina. 2010. PMID: 19996827 Clinical Trial.
-
[New drugs in the treatment of noninfectious uveitis].Arch Soc Esp Oftalmol. 2006 Dec;81(12):671-3. doi: 10.4321/s0365-66912006001200001. Arch Soc Esp Oftalmol. 2006. PMID: 17199159 Spanish. No abstract available.
-
Intravitreal infliximab in experimental endotoxin-induced uveitis.Eur J Ophthalmol. 2009 Sep-Oct;19(5):818-23. doi: 10.1177/112067210901900521. Eur J Ophthalmol. 2009. PMID: 19787603
-
The use of intraocular corticosteroids.Expert Opin Pharmacother. 2009 Oct;10(15):2511-25. doi: 10.1517/14656560903160671. Expert Opin Pharmacother. 2009. PMID: 19761356 Review.
-
Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17. Ophthalmology. 2014. PMID: 24359625
Cited by
-
Ocular vasculitis.Curr Rheumatol Rep. 2013 Sep;15(9):355. doi: 10.1007/s11926-013-0355-x. Curr Rheumatol Rep. 2013. PMID: 23888364 Review.
-
Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy.Mol Vis. 2014 Aug 4;20:1137-45. eCollection 2014. Mol Vis. 2014. PMID: 25253986 Free PMC article.
-
Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders.J Ophthalmic Inflamm Infect. 2014 Oct 15;4:26. doi: 10.1186/s12348-014-0026-8. eCollection 2014. J Ophthalmic Inflamm Infect. 2014. PMID: 25825604 Free PMC article. Review.
-
Local therapies for inflammatory eye disease in translation: past, present and future.BMC Ophthalmol. 2013 Aug 6;13(1):39. doi: 10.1186/1471-2415-13-39. BMC Ophthalmol. 2013. PMID: 23914773 Free PMC article.
-
Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts.J Ophthalmic Vis Res. 2012 Jan;7(1):39-44. J Ophthalmic Vis Res. 2012. PMID: 22737386 Free PMC article.
References
-
- Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–870. - PubMed
-
- Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin) Ophthalmology. 2007;114:855–859. - PubMed
-
- Bakri SJ, Risco M, Edwards AO, Pulido JS. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol. 2009;148:66–69. - PubMed
-
- Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol. 2009;20:166–174. - PubMed
-
- Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Opthalmologica. 2009;223:370–375. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
